Company intelligence / Profile preview

FWD

Ownership: Private
Development stage: Commercial

Overview

Forward Therapeutics is a biopharmaceutical company developing next-generation oral small molecule therapies for chronic inflammatory disorders. The company has raised significant venture funding ($50 million Series A in November 2023) to advance its pipeline, which focuses on validated immunology targets with the potential for blockbuster impact. No clinical results have been published yet.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly announced as of June 2025.

Beyond the preview

Go deeper on FWD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FWD.

Explore the full profile